Novo Nordisk’s Post-Wegovy Strategy Leads to 7% Share Drop
The shares of Danish pharmaceutical titan Novo Nordisk suffered a 7.7% dip — their most significant single-day loss since February. This plunge followed the company’s Capital Markets Day 2026 in London, where executives laid out a long-term growth strategy that failed to impress investors. CEO Mike Doustdar addressed the looming issue of semaglutide — the active ingredient in blockbuster drugs Wegovy and Ozempic — losing its key U.S. patent exclusivity in 2032. This market represents over half of Novo’s total sales.
Novo announced ambitious goals, including launching more than five drugs with “multi-blockbuster” potential by 2030 and generating over 150 billion Danish kroner ($23 billion) in pipeline sales by 2035. The company also projected compound annual revenue growth through 2030, aligning with pharmaceutical peers like Eli Lilly, AstraZeneca, and Merck. However, analysts believe these targets lack the financial firepower the market demands.
The company faces increasing pressure as Eli Lilly’s Zepbound is projected to outsell Wegovy by more than $7 billion this year. Novo’s share price has already plummeted over 70% from its 2023 peak, when it briefly held the title of Europe’s most valuable listed firm with a market capitalization exceeding $600 billion. Novo has also undergone a rebranding, transitioning from Novo Nordisk to simply Novo, indicating a comprehensive cultural and strategic overhaul.
Source: CNBC – Novo Shares Slide as Drugmaker Lays Out Post-Wegovy Growth Strategy